HealthcareServices

Infectious Disease Therapeutics Industry Poised for Rapid Growth, Forecast to Touch $200.86 Billion by 2030 at 5.7% CAGR

February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the infectious disease therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Infectious Disease Therapeutics Market in 2030?

The infectious disease therapeutics market size has seen significant growth in recent years. This market is projected to expand from $150.6 billion in 2025 to $160.84 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 6.8%. Historically, this growth was fueled by the substantial global prevalence of infectious diseases, the broad application of antibiotics and antivirals, government-led immunization initiatives, an expansion in pharmaceutical manufacturing capabilities, and enhanced investment in infectious disease research.

The infectious disease therapeutics market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $200.87 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. Factors driving this growth during the projection period include escalating antimicrobial resistance rates, a greater occurrence of infectious disease outbreaks, wider global vaccination coverage, an expanding need for new antiviral treatments, and enhanced public health readiness programs. Key trends for the forecast duration encompass a heightened emphasis on managing antimicrobial resistance, the accelerating creation of broad-spectrum treatments, the increasing use of combined drug therapies, the broadening of rapid-response treatments for outbreaks, and augmented funding for vaccine development and reserves.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15594&type=smp

What Drivers Are Influencing Production Trends In The Infectious Disease Therapeutics Market?

The anticipated increase in infectious disease prevalence is projected to fuel the expansion of the infectious disease therapeutics market in the future. These diseases are ailments triggered by pathogenic agents including bacteria, viruses, fungi, parasites, or prions. The surge in infectious diseases stems from several critical factors, such as shifts in climate and environmental disturbances, antimicrobial resistance, compromised immune systems, greater human-animal interaction, and ecological imbalances. Therapeutics for infectious diseases are crucial for managing infections, lowering illness and death rates, and curbing the dissemination of transmissible diseases within local areas and across wider populations. For example, data from October 2023, provided by the National Health Service (NHS) England, a UK government body, indicated that in 2022/23, hospitals recorded 147,285 primary admissions for urinary tract infections (UTI). Individuals over 65 years old accounted for 56% of these incidents, totaling 82,392 hospitalizations. The 80–84 age bracket experienced the most admissions, with 17,280 instances. Consequently, the growing incidence of infectious diseases acts as a catalyst for the infectious disease therapeutics market.

Which Segment Groups Are Influencing The Infectious Disease Therapeutics Market?

The infectious disease therapeutics market covered in this report is segmented –

1) By Type: Drugs, Vaccines

2) By Disease: Tuberculosis, HIV/AIDS, Influenza, Hepatitis, Other Diseases

3) By End-User: Hospitals And Clinics, Retail Pharmacies, Research Organizations, Other End Users

Subsegments:

1) By Drugs: Antibiotics, Antivirals, Antifungals, Antiparasitics, Other Therapeutic Drugs (Monoclonal Antibodies, Immunomodulators)

2) By Vaccines: Inactivated Vaccines, Live Attenuated Vaccines, Subunit Vaccines, Mrna Vaccines, Dna Vaccines, Toxoid Vaccines

What Trends Are Driving The Growth Trajectory Of The Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are prioritizing the integration of multispecific antibody platforms, such as the multispecific therapeutic antibody reactor (MSTAR), to elevate efficacy, broaden protection, and strengthen responsiveness against emerging viral threats. The multispecific therapeutic antibody reactor (MSTAR) represents an advanced multispecific antibody technology that combines multiple independent binding regions into a single therapeutic molecule, thereby enabling features like broad viral neutralization, simultaneous targeting of various epitopes, and swift adaptation to new variants. For instance, in September 2023, ModeX Therapeutics Inc, a US-based clinical stage biopharmaceutical company, obtained a contract from the Biomedical Advanced Research and Development Authority to further develop its multispecific antibody candidates. These candidates are designed for the treatment and prevention of viral infectious diseases including COVID 19 and influenza, characterized by broad activity against circulating viral strains, potential compatibility with gene-based delivery using mRNA or DNA vectors, and a multi-binding site architecture. This multispecific antibody approach enhances therapeutic outcomes by shortening development timelines, expanding protective coverage, and reducing the intricacy associated with combination biologic treatments.

Who Are The Primary Competitors In The Global Infectious Disease Therapeutics Market?

Major companies operating in the infectious disease therapeutics market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi SA, AstraZeneca, Novartis International AG, GlaxoSmithKline plc, Gilead Sciences Inc., Janssen Pharmaceuticals, Moderna Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim GmbH, BioCryst Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Which Regions Are Poised For Strategic Growth In The Infectious Disease Therapeutics Market?

North America was the largest region in the infectious disease therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the infectious disease therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Infectious Disease Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15594&type=smp

Browse Through More Reports Similar to the Global Infectious Disease Therapeutics Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Anti Infective Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report

Therapeutic Bcg Vaccines Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795